Literature DB >> 8394652

A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma.

M C Kinney1, R D Collins, J P Greer, J A Whitlock, N Sioutos, M E Kadin.   

Abstract

We describe nine patients with a primary Ki-1 (CD30)+ T-cell lymphoma containing numerous, often CD30-negative, small lymphocytes with irregular nuclei and a minor population of large CD30+ tumor cells. All previously described primary Ki-1+ lymphomas have been large-cell neoplasms. In this small-cell variant, the diagnosis of lymphoma was difficult to make because there was a predominance of small lymphocytes and, in some cases, clinical features suggested an inflammatory process. Patients were young (age range 0.3-40 years, median 14 years), and frequently had B symptoms (56%); sites of involvement were predominantly skin (78%) and lymph node (67%). The actuarial 2-year disease-free survival was 14%, and the overall survival was 51%. Two patients had a rapidly fatal course. In all cases histologic sections showed a predominance of small lymphocytes with marked nuclear irregularity and often a perivascular/intravascular distribution of CD30+ large cells. All cases had a T-cell phenotype. In four cases the large and small cells could be compared and had a similar aberrant T-cell phenotype. Large cells were CD30+, but only rare small cells expressed CD30. Cytogenetic studies revealed a t(2;5)(p23;q35) in four of four cases studied. Four patients had numerous large cells on repeat biopsies; two of these developed sheets of large CD30+ cells typical of anaplastic large-cell lymphoma (ALCL). These cases provide further evidence that primary Ki-1+ lymphoma has a morphologic spectrum that includes a small-cell variant. Although very different morphologically from previously described Ki-1+ ALCL, this small-cell variant is clearly part of the disease spectrum on the basis of clinical features, the presence of the t(2;5)(p23;q35), the aberrant T-cell phenotype in the small and large cells, as well as histologic progression seen in several patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394652     DOI: 10.1097/00000478-199309000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.

Authors:  S Pittaluga; I Wlodarska; K Pulford; E Campo; S W Morris; H Van den Berghe; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

Authors:  Rebecca L King; Linda N Dao; Ellen D McPhail; Elaine S Jaffe; Jonathan Said; Steven H Swerdlow; Christopher A Sattler; Rhett P Ketterling; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; Sarah E Gibson; Sarah L Ondrejka; Alina Nicolae; William R Macon; Surendra Dasari; Edgardo Parrilla Castellar; Andrew L Feldman
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

3.  Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group.

Authors:  Sarah Alexander; Jacqueline M Kraveka; Sheila Weitzman; Eric Lowe; Lynette Smith; James C Lynch; Myron Chang; Marsha C Kinney; Sherrie L Perkins; Joseph Laver; Thomas G Gross; Howard Weinstein
Journal:  Pediatr Blood Cancer       Date:  2014-08-23       Impact factor: 3.167

4.  Primary cutaneous anaplastic large cell lymphoma in a young child.

Authors:  Te-Yu Hung; Yu-Cheng Lin; Hai-Lun Sun; Min-Chang Liu
Journal:  Eur J Pediatr       Date:  2007-01-12       Impact factor: 3.183

5.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Authors:  B Falini; B Bigerna; M Fizzotti; K Pulford; S A Pileri; G Delsol; A Carbone; M Paulli; U Magrini; F Menestrina; R Giardini; S Pilotti; A Mezzelani; B Ugolini; M Billi; A Pucciarini; R Pacini; P G Pelicci; L Flenghi
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 6.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

7.  Small cell variant of Ki-1 lymphoma associated with myelofibrosis and a novel constitutional chromosomal translocation t(3;4) (q13;q12).

Authors:  W Yeo; N Wong; J Chow; W C Tsoi; P J Johnson; N Wickham
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

8.  ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.

Authors:  R L ten Berge; J J Oudejans; G J Ossenkoppele; K Pulford; R Willemze; B Falini; A Chott; C J Meijer
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

9.  Morphological variability of lymphohistiocytic variant of anaplastic large cell lymphoma (former lymphohistiocytic lymphoma according to the Kiel classification).

Authors:  Wolfram Klapper; Matthias Böhm; Reiner Siebert; Karl Lennert
Journal:  Virchows Arch       Date:  2008-05-14       Impact factor: 4.064

10.  Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study.

Authors:  J R Lopategui; L H Sun; J K Chan; M J Gaffey; H F Frierson; C Glackin; L M Weiss
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.